Exclusive interviews with leading policymakers that convey the true policy message that impacts markets.
Reporting on key macro data at the time of release.
- Emerging MarketsEmerging Markets
Real-time insight of emerging markets in CEMEA, Asia and LatAm region
- MNI ResearchMNI Research
Actionable insight on monetary policy, balance sheet and inflation with focus on global issuance. Analysis on key political risk impacting the global markets.
- About Us
Real-time Actionable Insight
Get the latest on Central Bank Policy and FX & FI Markets to help inform both your strategic and tactical decision-making.Free Access
Sign up now for free access to this content.
Please enter your details below and select your areas of interest.
Speaking to CNBC, Moderna CEO Stephane Bancel states that it could be two to six weeks before the efficacy of COVID-19 vaccines on the Omicron CVODI-19 variant is known with any clarity.
- Adds that it took four months for Delta variant to overtake Beta variant in the United States. Omicron is overtaking Delta in South Africa in a few weeks.
- Some hopes brought earlier today when Moderna announced that a modified vaccine that could handle Omicron could be avaliable by early-2022.